01.19.21 Tips For Using Bayesian Methods In Clinical Trial Designs
Clinical trials designed using Bayesian statistics are gaining prominence due to challenges raised by COVID-19. The former FDA director of biostatistics, Gregory Campbell, discusses best practices for securing regulatory approval when submitting a trial that employs Bayesian clinical trial design.
Gain some behind-the-scenes insights into the development of this new module and understand how your company can leverage East Alloy to conduct computationally intensive designs with ease, confidence, and speed.
One of the revelations of the COVID-19 pandemic is that the flexibility and potential of Bayesian designs goes far beyond the benefits connected to informed priors. This article summarizes a recent panel on COVID-19 drug discovery where biostatisticians and former regulators reflected on certain misconceptions about Bayesian methods.